Fueled by a growing pipeline of innovative GvHD drugs and an expected market surge from USD 1.4 billion<\/strong> in 2024 to impressive heights by 2034 at a CAGR of 8.2%<\/strong>, the momentum is undeniable. Behind this surge lies a rich pipeline of GvHD therapies with novel mechanisms of action, and frontrunners like CSL964 <\/strong>(CSL Behring), EQ001 <\/strong>(Equillium\/Biocon), MaaT013 <\/strong>(MaaT Pharma), and MC0518 <\/strong>(medac) are grabbing attention in late-stage development. As clinical trials progress and new breakthroughs emerge, the GvHD market is on the cusp of a new era. <\/p>\n\n\n\n Let\u2019s dive into these <\/em>late-stage GvHD therapies<\/em><\/a> that could reshape the future of GvHD care.<\/em><\/p>\n\n\n\n CSL Behring\u2019s ZEMAIRA<\/strong><\/p>\n\n\n\n CSL964 Alpha-1 Antitrypsin<\/strong>, an Alpha1-Proteinase Inhibitor (A1-PI) developed by CSL Behring<\/strong>, is under investigation for its potential in treating steroid-refractory acute graft-versus-host disease (aGvHD) and in preventing aGvHD in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The therapy is currently in Phase III trials for steroid-refractory aGvHD treatment<\/a> and is also being assessed in Phase II\/III studies for its role in aGvHD prevention.<\/p>\n\n\n\n Equillium\/Biocon\u2019s EQ001<\/strong><\/p>\n\n\n\n EQ001 (Itolizumab; Bmab600)<\/strong> is a pioneering immune-modulating antibody that targets the CD6 receptor to inhibit the activation and migration of pro-inflammatory T cells, which are key drivers of autoimmune and inflammatory diseases like GvHD, moderate-to-severe uncontrolled asthma, and lupus nephritis. By modulating the CD6-ALCAM pathway, Itolizumab selectively suppresses pathogenic effector T cells (Teffs) while sparing regulatory T cells (Tregs), which play a vital role in maintaining immune homeostasis.<\/p>\n\n\n\n EQ001 is currently being evaluated in a Phase III clinical trial as a first-line treatment for GvHD in combination with corticosteroids. In March 2025, Equillium announced topline results from the Phase III EQUATOR trial. Although the study did not meet its primary endpoints\u2014complete response (CR) or overall response rate (ORR) at Day 29 compared to placebo, Itolizumab did show statistically significant and clinically meaningful benefits in secondary endpoints, such as CR at Day 99, response duration, and failure-free survival. However, in April 2025, the FDA declined to grant Breakthrough Therapy designation or support Accelerated Approval, citing shortcomings in the EQUATOR trial data.<\/p>\n\n\n\n MaaT Pharma\u2019s MaaT013<\/strong><\/p>\n\n\n\n MaaT013<\/strong> is a donor-derived, standardized microbiome ecosystem therapy distinguished by its high microbial richness and diversity. It features the BUTYCORE bacterial consortium, known for generating anti-inflammatory short-chain fatty acids. This therapy aims to restore gut microbiome and immune system balance, enhancing immune tolerance and response to treat steroid-resistant, gastrointestinal-predominant acute GvHD. MaaT013 has received Orphan Drug Designation<\/strong> from both the US FDA and EMA.<\/p>\n\n\n\n In December 2024, MaaT Pharma presented promising new data from its Early Access Program at the ASH 2024 Annual Meeting. Following this, in January 2025, the company reported positive topline results from the Phase III ARES trial<\/strong>, where MaaT013 demonstrated a 62% overall GI response rate by Day 28, reinforcing its potential as a third-line treatment option for GI-aGvHD.<\/p>\n\n\n\n medac\u2019s MC0518<\/strong><\/p>\n\n\n\n MC0518 <\/strong>is an experimental mesenchymal stromal cell (MSC) therapy being developed by Medac GmbH, currently in clinical trials for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD) following allogeneic stem cell transplantation. The therapy harnesses the immune-modulating capabilities of MSCs to reduce the intense inflammatory response typical of SR-aGvHD, a condition in which donor immune cells attack the host\u2019s tissues despite corticosteroid treatment.<\/p>\n\n\n\n The ongoing IDUNN trial, a key Phase III study, is assessing the safety and effectiveness of MC0518 versus the best available therapy (BAT) in children and adolescents. The primary goal is to measure the overall response rate (ORR) at Day 28, while secondary endpoints include overall survival (OS) up to 24 months and freedom from treatment failure (FFTF) within six months. Preclinical studies have shown that MC0518 is well-tolerated in animal models, with no signs of tumor formation or major adverse effects.<\/p>\n\n\n\n In addition, a number of GvHD drugs<\/a> are currently in early-stage development. These include RLS-0071<\/strong> from ReAlta Life Sciences, Vimseltinib <\/strong>by Deciphera Pharmaceuticals, ASC-930 <\/strong>from ASC Therapeutics, RGI-2001 <\/strong>by REGiMMUNE, CYP-001<\/strong> by Cynata Therapeutics, arsenic trioxide (As2O3)<\/strong> from BioSenic (Medsenic), TRX103 (Tregs)<\/strong> by Tr1X, TCD601 (Siplizumab)<\/strong> from ITB-MED, F-652 <\/strong>by Evive Biotech, RHPRG4 <\/strong>from Lubris BioPharma, XBI302 <\/strong>by Xbiome, RG6287 <\/strong>from Genentech, ALTB-168<\/strong> by AltruBio, and SER-155<\/strong> by Seres Therapeutics.<\/p>\n\n\n\n A new wave of prophylaxis and chronic GVHD treatments is poised to hit the U.S. market, with CSL964 (Alpha 1 Antitrypsin) and RGI-2001<\/strong> leading the charge in 2027 and 2028<\/strong>. While uptake may start slow, CSL964 is projected to climb to a 7.5%<\/strong> peak market share, and RGI-2001 is expected to reach 4.2%<\/strong>, both within six years of launch.<\/p>\n\n\n\n Meanwhile, on the chronic GVHD front, arsenic trioxide, NIKTIMVO (Axatilimab), and REZUROCK (belumosudil) <\/strong>are eyeing launches between 2028 and 2030<\/strong>. Among them, REZUROCK is forecast to take the lead with a 10%<\/strong> market share, while arsenic trioxide and NIKTIMVO are each projected to hit 8%<\/strong>. Market peaks for these therapies are expected between five to six years post-launch, signaling steady yet impactful adoption curves.<\/p>\n\n\n\n![\"Late-stage-GvHD-Pipeline-Therapies\"](\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/04113911\/Late-stage-GvHD-Pipeline-Therapies-1024x202.png\")
<\/a><\/figure>\n\n\n\n
![\"Graft](\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/04113839\/Graft-Versus-Host-Disease-Market-Outlook-1024x194.png\")
<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"